The Capital Market Authority (“CMA") announces the issuance of its Board resolution dated 1445/05/20 AH corresponding to 2023/12/04 AD approving the application of Middle East Healthcare Company (“Issuer") for the registration and public offering of the debt instruments within a program that does not exceed the value of (1.5) billion Riyal. The prospectus will be published within sufficient time prior to the start of the subscription period.

The prospectus includes all relevant information that the investor needs to know before making an investment decision, including the financial statements of the issuer and adequate information about its activities and management, in addition to the details of the issuance program mentioned above.

A subscription decision without reading the prospectus carefully and fully reviewing its content, may involve high risks. Therefore, investors should carefully read the prospectus which contains detailed information about the issuer, offering and risk factors. Thus, providing potential investors the ability to evaluate the viability of investing in the offering, taking into consideration the associated risks. If the prospectus proves difficult to understand, it is recommended to consult with an authorized financial advisor prior to making any investment decision.

The CMA's approval on the application should not be considered as a recommendation to subscribe in the offering or the debt instruments of the issuer. The CMA's approval on the application merely means that the legal requirements as per the Capital Market Law and its Implementing Regulations have been met.

The CMA's approval on the application shall be valid for (6) months from the CMA Board resolution date. The approval shall be deemed cancelled if the offering and listing of the issuer's first intended tranche of the debt instruments of the program is not completed within this period.